Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Overview | 10 | 1 |
| Therapeutics Development | 11 | 1 |
| Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) Overview | 11 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Therapeutics under Development by Companies | 12 | 2 |
| Peripheral T-Cell Lymphomas (PTCL) Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Products under Development by Companies | 17 | 3 |
| Peripheral T-Cell Lymphomas (PTCL) Companies Involved in Therapeutics Development | 20 | 24 |
| AB Science SA | 20 | 1 |
| Affimed GmbH | 21 | 1 |
| arGEN-X BV | 22 | 1 |
| Bayer AG | 23 | 1 |
| Boehringer Ingelheim GmbH | 24 | 1 |
| Celgene Corporation | 25 | 1 |
| CerRx, Inc. | 26 | 1 |
| Chipscreen Biosciences Ltd | 27 | 1 |
| CSPC Pharmaceutical Group Limited | 28 | 1 |
| Eisai Co., Ltd. | 29 | 1 |
| Genosco | 30 | 1 |
| Incyte Corporation | 31 | 1 |
| Japan Tobacco Inc. | 32 | 1 |
| Johnson &Johnson | 33 | 1 |
| Mundipharma International Ltd | 34 | 1 |
| Ono Pharmaceutical Co., Ltd. | 35 | 1 |
| Onxeo SA | 36 | 1 |
| Pfizer Inc. | 37 | 1 |
| Pharma Mar, S.A. | 38 | 1 |
| Portola Pharmaceuticals, Inc. | 39 | 1 |
| Rhizen Pharmaceuticals S.A. | 40 | 1 |
| Seattle Genetics, Inc. | 41 | 1 |
| Solasia Pharma K.K. | 42 | 1 |
| Spectrum Pharmaceuticals, Inc. | 43 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Therapeutics Assessment | 44 | 11 |
| Assessment by Monotherapy Products | 44 | 1 |
| Assessment by Target | 45 | 3 |
| Assessment by Mechanism of Action | 48 | 3 |
| Assessment by Route of Administration | 51 | 2 |
| Assessment by Molecule Type | 53 | 2 |
| Drug Profiles | 55 | 176 |
| AFM-13 Drug Profile | 55 | 4 |
| ARGX-110 Drug Profile | 59 | 4 |
| belinostat Drug Profile | 63 | 9 |
| brentuximab vedotin Drug Profile | 72 | 24 |
| Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma Drug Profile | 96 | 1 |
| cerdulatinib Drug Profile | 97 | 4 |
| copanlisib hydrochloride Drug Profile | 101 | 4 |
| darinaparsin Drug Profile | 105 | 3 |
| denileukin diftitox Drug Profile | 108 | 2 |
| enasidenib Drug Profile | 110 | 6 |
| fenretinide Drug Profile | 116 | 2 |
| forodesine hydrochloride Drug Profile | 118 | 2 |
| ICG-122 Drug Profile | 120 | 1 |
| lenalidomide Drug Profile | 121 | 14 |
| masitinib Drug Profile | 135 | 14 |
| MEDI-570 Drug Profile | 149 | 1 |
| mitoxantrone hydrochloride Drug Profile | 150 | 2 |
| nivolumab Drug Profile | 152 | 28 |
| NL-101 Drug Profile | 180 | 2 |
| plitidepsin Drug Profile | 182 | 4 |
| pralatrexate Drug Profile | 186 | 6 |
| romidepsin Drug Profile | 192 | 3 |
| RP-6530 Drug Profile | 195 | 2 |
| ruxolitinib phosphate Drug Profile | 197 | 13 |
| SH-7129 Drug Profile | 210 | 1 |
| Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma Drug Profile | 211 | 1 |
| temsirolimus Drug Profile | 212 | 2 |
| TGR-1202 Drug Profile | 214 | 7 |
| tipifarnib Drug Profile | 221 | 3 |
| tucidinostat Drug Profile | 224 | 3 |
| volasertib trihydrochloride Drug Profile | 227 | 4 |
| Peripheral T-Cell Lymphomas (PTCL) Dormant Projects | 231 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Discontinued Products | 232 | 1 |
| Peripheral T-Cell Lymphomas (PTCL) Product Development Milestones | 233 | 12 |
| Featured News &Press Releases | 233 | 1 |
| Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation | 233 | 1 |
| Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma | 233 | 1 |
| Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma | 234 | 1 |
| Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor | 234 | 1 |
| Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma | 235 | 1 |
| Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan | 235 | 1 |
| Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015 | 236 | 2 |
| Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP | 238 | 1 |
| Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma | 239 | 1 |
| Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma | 240 | 1 |
| Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology | 241 | 1 |
| May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3 | 241 | 2 |
| Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China | 243 | 1 |
| Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China | 243 | 1 |
| Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation | 244 | 1 |
| Appendix | 245 | 2 |
| Methodology | 245 | 1 |
| Coverage | 245 | 1 |
| Secondary Research | 245 | 1 |
| Primary Research | 245 | 1 |
| Expert Panel Validation | 245 | 1 |
| Contact Us | 245 | 1 |
| Disclaimer | 246 | 1 |
